Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells

Stem Cells

Volumn 33, Issue 3, 2015, Pages 870-879

  Barclay, Sharlie L ^a   Yang, Yimin ^a   Zhang, Siruo ^a   Fong, Ryan ^a   Barraza, Alfonso ^a   Nolta, Jan A ^a   Torbett, Bruce E ^b   Abedi, Mehrdad ^a   Bauer, Gerhard ^a   Anderson, Joseph S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Gene therapy; Hematopoietic cells; Human immunodeficiency virus; Lentiviral vector

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD25 ANTIBODY; CD34 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURST FORMING UNIT E; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL PROTECTION; CELL SURFACE; CFU COUNTING; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; ERYTHROCYTE; GENOTOXICITY; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MEGAKARYOCYTE; MOUSE; NONHUMAN; PHENOTYPE; STEM CELL GENE THERAPY; VIRAL GENE THERAPY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CYTOLOGY; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; IMMUNOLOGY; KNOCKOUT MOUSE; LENTIVIRINAE; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROCEDURES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LENTIVIRUS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; TRANSDUCTION, GENETIC;

EID: 84923248072     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1919     Document Type: Article

References (19)

1. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
2. Hütter G, Thiel E,. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2. AIDS 2011; 25: 273-274.
3. Bauer G, Anderson JS. Stem cell transplantation in the context of HIV-How can we cure HIV infection? Expert Rev Clin Immunol 2014; 10: 107-116.
4. Zhen A, Kitchen S,. Stem-cell-based gene therapy for HIV infection. Viruses 2013; 6: 1-12.
5. Strayer DS, Akkina R, Bunnell BA, et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 2005; 11: 823-842.
6. Trobridge GD, Wu RA, Beard BC, et al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 2009; 4: e7693.
7. Younan PM, Polacino P, Kowalski JP, et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 2013; 122: 179-187.
8. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15: 285-292.
9. Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368-371.
10. Podsakoff GM, Engel BC, Carbonaro DA, et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005; 12: 77-86.
11. DiGiusto D, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 36: 36ra43.
12. Anderson JS, Javien J, Nolta JA, et al. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 2009; 17: 2103-2114.
13. Walker JE, Chen RX, McGee J, et al. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol 2012; 86: 5719-5729.
14. Wang CX, Sather BD, Wang X, et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014; 124: 913-923.
15. Kalomoiris S, Lawson J, Chen RX, et al. CD25 preselective anti-HIV vectors for improved HIV gene therapy. Hum Gene Ther Methods 2012; 23: 366-375.
16. Grant AJ, Roessler E, Ju G, et al. The interleukin 2 receptor (IL-2R) the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc Natl Acad Sci USA 1992; 89: 2165-2169.
17. Minami Y, Kono T, Miyazaki T, et al. The IL-2 receptor complex: Its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245-267.
18. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
19. Anderson J, Li MJ, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-sderived T cells. Mol Ther 2007; 15: 1182-1188.